Literature DB >> 17127271

Genetic basis of respiratory distress syndrome.

Mikko Hallman1, Ritva Haataja.   

Abstract

Respiratory distress syndrome (RDS) is a multifactorial developmental disease caused by lung immaturity and presenting as high-permeability lung edema ("hyaline membrane disease"). It is characterized by a transient deficiency of alveolar surfactant during the first week of life. During the first few days of life, the alveolar surfactant pool size increases up to that in the controls. The allelic variants of the genes encoding the surfactant proteins (SP) SP-A1, SP-A2, SP-B, and SP-C have been associated with RDS. The main SP-A haplotype, interactively with the SP-B Ile131Thr polymorphism and with constitutional and environmental factors, influence the risk. Case reports on mutations with partially functional SP-B have been published. The genetic susceptibility factors depend on the degree of prematurity at birth, consistent with sequential differentiation of the lung and gestation-dependent differences in clinical presentation. The preferentially type 2 cell expressed genes involved in critical functions (such as ATP-binding cassette transporter, ABCA3), those involved in susceptibility to acute lung damage, and those with known susceptibility to other severe lung diseases (such as G protein-coupled receptor for asthma susceptibility, GPR154 alias GPRA) will possibly serve as candidate genes in future studies. RDS associated with near-term and term births may have a different genetic predisposition and pathogenesis compared to RDS after very preterm birth. As we learn more about the molecular consequences of allelic variation, new therapies based on a new generation of surfactant diagnostics and individualized therapies may follow.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127271     DOI: 10.2741/2263

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates.

Authors:  K K Ryckman; J M Dagle; K Kelsey; A M Momany; J C Murray
Journal:  J Perinatol       Date:  2011-09-29       Impact factor: 2.521

Review 2.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Authors:  Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

3.  Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany.

Authors:  Matthias Griese; Melanie Haug; Frank Brasch; Achim Freihorst; Peter Lohse; Rüdiger von Kries; Theodor Zimmermann; Dominik Hartl
Journal:  Orphanet J Rare Dis       Date:  2009-12-12       Impact factor: 4.123

Review 4.  Genetic disorders of surfactant dysfunction.

Authors:  Susan E Wert; Jeffrey A Whitsett; Lawrence M Nogee
Journal:  Pediatr Dev Pathol       Date:  2009 Jul-Aug

5.  Umbilical cord levels of macrophage migration inhibitory factor in neonatal respiratory distress syndrome

Authors:  Süleyman Bayraktar; Bilge Tanyeri Bayraktar; Ülkan Kılıç
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

6.  Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress.

Authors:  Milad Rezvani; Juliane Wilde; Patricia Vitt; Beena Mailaparambil; Ruth Grychtol; Marcus Krueger; Andrea Heinzmann
Journal:  Dis Markers       Date:  2013-10-31       Impact factor: 3.434

Review 7.  What's new in surfactant? A clinical view on recent developments in neonatology and paediatrics.

Authors:  Jasper V Been; Luc J I Zimmermann
Journal:  Eur J Pediatr       Date:  2007-05-22       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.